Quarterly report pursuant to Section 13 or 15(d)

REVENUES

v3.23.1
REVENUES
3 Months Ended
Mar. 31, 2023
REVENUES  
REVENUES

3.

Revenues

Revenues disaggregated by category were as follows (in thousands):

Three Months Ended March 31, 

2023

    

2022

Product sales:

Gross product sales

$

33,198

$

22,618

Discounts and allowances

(9,453)

(6,421)

Total product sales, net

23,745

16,197

Revenues from collaborations:

License revenues

208

Royalty, delivery of drug supplies and others

2,325

330

Total revenues from collaborations

2,325

538

Government contract

Total revenues

$

26,070

$

16,735

Revenue from product sales are related to sales of our commercial products, TAVALISSE and REZLIDHIA, to our specialty distributors. For detailed discussions of our revenues from collaboration and government contract, see “Note 4 – Sponsored Research and License Agreements and Government Contract”.

Our net product sales include gross product sales, net of chargebacks, discounts and fees, government and other rebates and returns. The following tables summarize the activities in chargebacks, discounts and fees, government and other rebates and returns that were accounted for within revenue reserves and refund liability, for each of the periods presented (in thousands):

Chargebacks,

Government

Discounts and

and Other

Fees

Rebates

Returns

Total

Balance as of January 1, 2023

    

$

6,213

$

2,636

$

3,296

$

12,145

Provision related to current period sales

7,231

1,795

197

9,223

Credit or payments made during the period

(5,777)

(1,422)

(81)

(7,280)

Balance as of March 31, 2023

 

$

7,667

$

3,009

$

3,412

$

14,088

Chargebacks,

Government

Discounts and

and Other

Fees

Rebates

Returns

Total

Balance as of January 1, 2022

    

$

3,404

$

2,494

$

2,017

$

7,915

Provision related to current period sales

4,345

1,397

378

6,120

Credit or payments made during the period

(3,322)

(1,227)

(31)

(4,580)

Balance as of March 31, 2022

 

$

4,427

$

2,664

$

2,364

$

9,455

Of the $9.5 million discounts and allowances from gross product sales for the three months ended March 31, 2023, $9.2 million was accounted for as additions to revenue reserves and refund liability and $0.3 million as reductions in accounts receivable (as it relates to allowance for prompt pay discount) and prepaid and other current assets (as it relates to certain chargebacks and other fees that were prepaid) in the condensed balance sheet.

Of the $6.4 million discounts and allowances from gross product sales for the three months ended March 31, 2022, $6.1 million was accounted for as additions to revenue reserves and refund liability and $0.3 million as reductions in accounts receivable (as it relates to allowance for prompt pay discount) and prepaid and other current assets (as it relates to certain chargebacks and other fess that were prepaid) in the condensed balance sheet.

The following table summarizes the percentages of revenues from each of our customers who individually accounted for 10% or more of the total net product sales and revenues from collaborations:

Three Months Ended March 31, 

2023

    

2022

McKesson Specialty Care Distribution Corporation

45%

38%

Cardinal Healthcare

24%

28%

ASD Healthcare and Oncology Supply

22%

31%